Literature DB >> 8335819

Coexistence of sudden cardiac death and end-stage heart failure in familial hypertrophic cardiomyopathy.

G M Hecht1, H G Klues, W C Roberts, B J Maron.   

Abstract

OBJECTIVES: The purpose of this study was to determine the occurrence of sudden cardiac death or end-stage heart failure, two phases of the natural history of hypertrophic cardiomyopathy, in closely related relatives.
BACKGROUND: Hypertrophic cardiomyopathy is a genetically transmitted cardiac disease with a particularly diverse clinical and morphologic spectrum. Premature death usually occurs either suddenly or as a result of progressive congestive heart failure.
METHODS: We describe seven families with genetically transmitted hypertrophic cardiomyopathy that were studied with echocardiography or necropsy, or both, and were selected because they were known to include relatives who had incurred either premature sudden cardiac death or the end-stage phase of the disease.
RESULTS: The seven families comprised 128 relatives; 26 died suddenly, and 9 developed end-stage heart failure (including 2 with heart transplantation) associated with left ventricular cavity enlargement, wall thinning or decreased contractility, alone or in combination, as well as loss of outflow obstruction. Patients who died suddenly did so at younger ages (23 +/- 10 years) than did patients who died or required heart transplantation in the end-stage phase of hypertrophic cardiomyopathy (42 +/- 8 years, p < 0.001).
CONCLUSIONS: This study demonstrates that family members with hypertrophic cardiomyopathy, despite a common genetic substrate, may exhibit markedly diverse and distinct expressions of the natural history of their disease, which occur at widely separated periods of life.

Entities:  

Mesh:

Year:  1993        PMID: 8335819     DOI: 10.1016/0735-1097(93)90054-5

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  11 in total

1.  Swimming exercise in infancy has beneficial effect on the hearts in cardiomyopathic Syrian hamsters.

Authors:  Mariko Tatsuguchi; Eriko Hiratsuka; Shuichi Machida; Toshio Nishikawa; Shin-Ichiro Imamura; Satoru Shimizu; Masahiko Nishimura; Issei Komuro; Yoshiyuki Furutani; Michiko Furutani; Hiroaki Nagao; Keiko Komatsu; Hiroshi Kasanuki; Rumiko Matsuoka
Journal:  J Muscle Res Cell Motil       Date:  2004       Impact factor: 2.698

2.  Malignant familial hypertrophic cardiomyopathy in a family with a 453Arg-->Cys mutation in the beta-myosin heavy chain gene: coexistence of sudden death and end-stage heart failure.

Authors:  Y L Ko; J J Chen; T K Tang; J J Cheng; S Y Lin; Y C Liou; P Kuan; C W Wu; W P Lien; C C Liew
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

3.  Facts and ideas from anywhere.

Authors:  William C Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2009-01

4.  Mice expressing mutant myosin heavy chains are a model for familial hypertrophic cardiomyopathy.

Authors:  K L Vikstrom; S M Factor; L A Leinwand
Journal:  Mol Med       Date:  1996-09       Impact factor: 6.354

5.  Risk factors and stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy.

Authors:  B J Maron; F Cecchi; W J McKenna
Journal:  Br Heart J       Date:  1994-12

6.  Cardiac troponin T Arg92Trp mutation and progression from hypertrophic to dilated cardiomyopathy.

Authors:  N Fujino; M Shimizu; H Ino; K Okeie; M Yamaguchi; T Yasuda; H Kokado; H Mabuchi
Journal:  Clin Cardiol       Date:  2001-05       Impact factor: 2.882

7.  Prognosis of hypertrophic cardiomyopathy: assessment by 123I-BMIPP (beta-methyl-p-(123I)iodophenyl pentadecanoic acid) myocardial single photon emission computed tomography.

Authors:  T Nishimura; S Nagata; T Uehara; T Morozumi; Y Ishida; T Nakata; O Iimura; C Kurata; Y Wakabayashi; H Sugihara; K Otsuki; T Wada; Y Koga
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

8.  Novel ALPK3 mutation in a Tunisian patient with pediatric cardiomyopathy and facio-thoraco-skeletal features.

Authors:  Hager Jaouadi; Lilia Kraoua; Lilia Chaker; Alexandre Atkinson; Valérie Delague; Nicolas Levy; Rym Benkhalifa; Ridha Mrad; Sonia Abdelhak; Stéphane Zaffran
Journal:  J Hum Genet       Date:  2018-07-25       Impact factor: 3.172

9.  Impact of systolic dysfunction in genotyped hypertrophic cardiomyopathy.

Authors:  Noboru Fujino; Tetsuo Konno; Kenshi Hayashi; Akihiko Hodatsu; Takashi Fujita; Toyonobu Tsuda; Yoji Nagata; Masa-aki Kawashiri; Hidekazu Ino; Masakazu Yamagishi
Journal:  Clin Cardiol       Date:  2012-11-29       Impact factor: 2.882

10.  Metabolic crosstalk between the heart and liver impacts familial hypertrophic cardiomyopathy.

Authors:  Jason A Magida; Leslie A Leinwand
Journal:  EMBO Mol Med       Date:  2014-02-24       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.